Program

Home

Program

Thursday 23 June 2011
Joint Session with the 6th International Workshop on Clinical Pharmacology of Hepatitis Therapy
08:45 - 09:15h Overview on the Protease inhibitor trials/ clinical implications
Invited speaker: Stefan Zeuzem MD
09:15 - 09:30h Discussion
09:30 - 10:00h Overview on new classes of HCV inhibitors (other than Protease/Polymerase Inhibitors)
Invited speaker: Ira Jacobson MD
10:00 - 10:15h Discussion
10:15 - 10:45h

Break

10:45 - 11:15h

Viral Dynamics and Resistance: Implications for HCV drug development
Invited speaker: Robert Schooley MD

11:15 - 11:30h Discussion
11:30 - 12:00h

Influence of genetic markers on treatment outcome
Invited speaker: John McHutchison MD

12:00 - 12:15h  Discussion
12:15 - 12:45h Interferon Responsiveness to Bridge PegInterferon Ribavirin Treated and Untreated Subjects
Invited speaker: Pravin Jadhav PhD
12:45 - 13:00h Discussion and closure of the joint session
13:00 - 14:15h

Lunch

Session 1  HCV replication dynamics
14:15 - 14:30h  Opening
14:30 - 15:00h Evolution of RNA viruses -- Replication Space
Invited speaker: Isabel Novella PhD
15:00 - 15:15h Discussion
15:15 - 16:30h Abstract driven presentations and Discussion
16:30 - 17:00h

Break 

Session 2  HCV pathogenesis
17:00 - 17:30h HCV Viral Entry Process
Invited speaker: Matt Evans PhD
17:30 - 17:45h Discussion
17:45 - 18:45h Abstract driven presentations and Discussion
Friday 24 June 2011
Session 3 Clinical relevance and management of HCV drug resistance
08:30 - 09:00h Clinical focus on Cholesterol Synthesis
Invited speaker: Raymond Chung MD
09:00 - 09:15h Discussion
09:15 - 10:30h  Abstract driven presentations and Discussion
10:30 - 11:00h

Break

Session 4 Novel HCV Inhibitors - I
11:00 - 11:30h Structure based theory and drug development program
Invited speaker: Celia Schiffer PhD
11:30 - 11:45h Discussion
11:45 - 13:00h Abstract driven presentations and Discussion
13:00 - 14:00h

Lunch 

Session 5 Novel HCV Inhibitors - II
14:00 - 15:15h Abstract driven presentations and Discussion
15:15 - 15:45h

Break

Session 6 Technologies for assessment of resistance
15:45 - 16:15h Ultra Deep Sequencing Technology
Invited speaker: Richard Barnard PhD
16:15 - 16:30h Discussion
16:30 - 17:15h Abstract driven presentations and Discussion
17:15 - 17:30h Final Discussion and Adjournment
  • -------------------------
    Chung, Raymond

    Raymond Chung MD

    Cholesterol Synthesis (Clinical Focus)




  • -------------------------

    Matt Evans PhD

    HCV Viral Entry Process




  • --------------------------

    Isabel Novella PhD

    Evolution of RNA viruses




  • -------------------------

    Celia Schiffer PhD

    Structure Base Theory and Drug Development Program




  • -------------------------

    Richard Barnard PhD

    Ultra Deep Sequencing



  • Speakers Joint Session

    Ira Jacobson MD

    Overview of the new classes of HCV inhibitors (other than Protease and Polymerase Inhibitors)


    ...

  • -------------------------

    Pravin Jadhav PhD

    Interferon Responsiveness to Bridge Treatment Naive and Experienced Patients

    ...

  • -------------------------

    John McHutchison MD

    Influence of IL28B and other genetic markers on treatment outcomes


    ...

  • -------------------------

    Robert Schooley MD

    Modeling / New Therapies: Implications of viral dynamics and resistance considerations for optimizing Hepatitis C therapies


    ...

  • -------------------------

    Stefan Zeuzem MD

    Overview on the Protease inhibitor trials / Clinical Implications


    ...

Other Invited Speakers, Bios and Pictures will be added soon

Richard Barnard PhD, Merck Research Laboratories, USA

 

6th_HEPC_resistance_new

Program

Important Dates

Registration Timeline
Early:      15 April 2011
Regular:  16 April - 13 May 2011
Late:       14 May - 11 June 2011

Abstract Submission:
Extended Deadline:  20 May 2011